Candin Safety & Efficacy Study for the Treatment of Warts

Completed · Phase 2

Conditions studied: Warts, Human Papilloma Virus

In brief

The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).

Key facts

Study ID

NCT01757392

Run by

Nielsen BioSciences, Inc.

People needed

39

Starts

2012-09-01

Expected to finish

2014-12-01

Last updated by the study team

2021-02-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have at least 3 and not more than 10 common warts not located on the palms or digits
• Positive DTH response to Candin® required

You may not qualify if…

• No previous medical treatment for warts other than OTC
• No immunocompromising medical conditions or medicines allowed
• No preexisting inflammatory conditions at treatment site allowed

Where it is running

• Johnson Dermatology — Fort Smith, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.